Catalyst Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Florida, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
355 Alhambra Cir Ste 801, Coral Gables, ...Phone Number
(305) 420-3200Website
www.catalystpharma.comRevenue
$597 MillionStock Symbol
CPRXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
4
1
1
1
1
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Explore more
Catalyst Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Catalyst Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Catalyst Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Catalyst Pharmaceuticals
Click to see if Catalyst Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Catalyst Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Catalyst Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Catalyst Pharmaceuticals has new funding data
Check if Catalyst Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Catalyst Pharmaceuticals recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Catalyst Pharmaceuticals
Compare insights from companies similar to Catalyst Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Catalyst Pharmaceuticals
$597M
51-200
Public
$20.1M
2002
MK
Michael KalbExecutive Vice President & Chief Financial Officer
Company Profile Activity
Activity Insights
Catalyst Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Catalyst Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals financials insights
Gather financial insights about Catalyst Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2006
Stock Offering
$20.1M
Catalyst Pharmaceuticals Tech Stack
A closer look at the technologies used by Catalyst Pharmaceuticals
See more technologies
Most Recent Scoops
Project
Contracts
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Open Position
Hiring Plans
Catalyst Pharmaceuticals has more open roles in Human Resources than it has had at any time in the past 12 months. Technologies mentioned include: Microsoft SharePoint.
Hiring Plans
Open Position
Catalyst Pharmaceuticals News & Media
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or...Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026Angelini Pharma agrees $4.1bn Catalyst Pharmaceuticals acquisition - Investment Monitor
Italian pharmaceutical group Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals in a cash deal worth about $4.1bn.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Catalyst Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic... Read More
